 CAMBRIDGE, Mass., May 07, 2021 GLOBE NEWSWIRE -- Trillium Therapeutics Inc. NASDAQTSX: TRIL, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the three months ended March 31, 2021. All financial amounts in this news release are in United States dollars, unless otherwise stated. 